GlobeNewsWire
04 Aug 2026, 21:45 UTC · 6w ago
Verdict
Headline takes no side. We score CELC −0.80 across three claims — strongly bearish.
−0.80strongly bearish
More negative than 89% of ticker scores this week
What the story claims
3 claims · scored −1 bearish … +1 bullish
Celcuity announced a commercial launch date for its FDA-approved breast cancer therapy Revtorpyk in late Q3 2026, which is later than analyst expectations.
So whatDelayed commercialization of a primary product directly impacts short-term revenue projections and investor sentiment, as evidenced by the initial 17.6% stock price drop.
More negative than 94% of claims this week
Law firm Pomerantz LLP is investigating whether Celcuity and its officers engaged in securities fraud or unlawful business practices.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Search tags
More negative than 85% of claims this week
The FDA has granted approval for Celcuity's breast cancer therapy Revtorpyk (gedatolisib).
More positive than 62% of claims this week
Which stocks this story touches
More negative than 89% of ticker scores this week
The company is facing a securities fraud investigation and saw a significant stock price drop due to a delayed product launch.
More negative than 85% of ticker scores this week
A class action lawsuit has been filed against the company.
More negative than 84% of ticker scores this week
The company is the subject of an investigation into claims on behalf of investors.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
38m ago
−9.2%
Price agrees with the score
$84.00 vs $92.49 close before publication (Aug 4) · not market-adjusted
CELC chart →